Lakshmi Jayashankar

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Rhea N. Coler, Tracey A. Day, Ruth D. Ellis et al. · npj Vaccines · 2018 · 158 citations · Full text

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH‐F3+GLA‐SE

Rhea N. Coler, Malcolm S. Duthie, Kimberly A. Hofmeyer et al. · Clinical & Translational Immunology · 2015 · 149 citations · Full text

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

Adam Penn‐Nicholson, Michèle Tameris, Erica Smit et al. · The Lancet Respiratory Medicine · 2018 · 146 citations

Vaccination, Vaccine Safety, Pulmonary Tuberculosis +11

Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults

Marília Santini-Oliveira, Rhea N. Coler, Jucara F. C. Parra et al. · Vaccine · 2015 · 114 citations

Vaccination, Vaccine Safety, Vaccine Development +10

Bovine Adenoviral Vector–based H5N1 Influenza Vaccine Overcomes Exceptionally High Levels of Pre-existing Immunity Against Human Adenovirus

Neetu Singh, Aseem Pandey, Lakshmi Jayashankar et al. · Molecular Therapy · 2008 · 72 citations · Full text